标题
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
作者
关键词
-
出版物
NEW ENGLAND JOURNAL OF MEDICINE
Volume 388, Issue 8, Pages 719-732
出版商
Massachusetts Medical Society
发表日期
2023-02-16
DOI
10.1056/nejmoa2214676
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
- (2022) Fred Saad et al. JOURNAL OF CLINICAL ONCOLOGY
- Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?
- (2022) Simon Van Wambeke et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
- (2022) Thomas Powles et al. NATURE MEDICINE
- Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future
- (2022) L.C. Ardolino et al. ANNALS OF ONCOLOGY
- Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
- (2022) Silke Gillessen et al. EUROPEAN UROLOGY
- BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.
- (2022) Maha H. A. Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer
- (2021) Julie N Graff et al. Future Oncology
- Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
- (2021) Johann S de Bono et al. LANCET ONCOLOGY
- Recent Advances in the Management of Metastatic Prostate Cancer
- (2021) Nicolas Sayegh et al. JCO Oncology Practice
- Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
- (2021) Ursula M. Vogl et al. EUROPEAN JOURNAL OF CANCER
- Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC
- (2021) Oliver Sartor et al. Future Oncology
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) C. Parker et al. ANNALS OF ONCOLOGY
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA
- (2017) Stéphane Oudard et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started